News

December 1, 2016

See how the efficacy & safety of therapeutic fibrinolysis can be improved. Read more in the premier cardiology journal JACC. JACC Logo 2

November 18, 2015

TSI, LLC nominated as a Top Biopharma Project to Watch in Cardiovascular by Elsevier Business Intelligence’s Therapeutic Area Partnership Conference organizers. Read more: TSI LLC nominated as a Top Biopharma Project to Watch

June 2, 2015

TSI, LLC announces a collaboration with National Institute of Neurological Disorders and Stroke (NINDS) to test a novel thrombolytic regimen for the treatment of Acute Ischemic Stroke in a Phase IIa clinical trial.  Read more: TSI, LLC to Collaborate With National Institutes of Health   NINDS Logo

April 1, 2015

A scientific paper by V. Gurewich, MD, TSI’s CSO, is published in the journal PloS One. The paper describes TSI's new drug candidate, a synergistic sequence of low doses of tPA and mutant prourokinase, a more efficient, safer fibrinolytic regimen than can be achieved with traditional monotherapy.  Read more. Screen Shot 2015-04-01 at 5.23.04 PM

February 4, 2015

The International Stroke Conference is the world’s largest meeting dedicated to the science and treatment of cerebrovascular disease. We will be there. Read more.  

October 7, 2014

TSI Selected to Present at Cavendish Global Health Impact Forum.  Cavendish Global uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences, "TSI to present at the Cavendish Global Health Impact Forum, November 10-13, 2014"

February 19, 2013

Cardio. Eng. & Tech. – Scientific paper published comparing TSI’s stroke therapeutic to other thrombolytics and their mechanisms of action, “Fibrinolytic Mechanisms of tPA, prouPA, Mutant prouPA and Their Implications for Therapeutic Thrombolysis

Comments are closed.